Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.

Hallucinogen persisting perceptual disorder: a scoping review covering frequency, risk factors, prevention, and treatment

Abstract

INTRODUCTION: Hallucinogen persisting perception disorder (HPPD) affects a subset of persons who use hallucinogens and is defined as the repeated experience of hallucinations and other perceptual disturbances as a result of prior intoxications. As select hallucinogens are under development for the treatment of selectmental disorders, there is a need to better characterize this disorder. AREAS COVERED: A scoping review of the literature on HPPD was completed from inception to July 2021. Topics covered in the review herein include treatments for HPPD, prevalence or incidence data on HPPD among different classes of hallucinogens, risk factors for HPPD, and data pertaining to the pathophysiology of HPPD. EXPERT OPINION: Hallucinogen persisting perception disorder appears to be an uncommon yet serious event associated with prior hallucinogen exposure. The renewed interest in psychedelics as potential treatment options for select mental disorders, especially agents with hallucinogenic potential, provides the impetus to characterize HPPD in its frequency, risk and protective factors, key characteristics, as well as other clinical and treatment-related factors.

Overview

Integrity signals

Registry

Crossref · 10.1080/14740338.2022.2063273

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 46 references

Research works printed but not linked: 12

  1. Lerner A, 2014, Isr J Psychiatry Relat Sci, 51, 296
  2. 2013, Diagnostic and statistical manual of mental disorders
  3. Levels of Evidence Working Group, 2011, The Oxford 2011 levels of evidence
  4. Kurtom M, 2019, Cureus, 11, e4077
  5. Lerner A, 2014, J Psychiatry, 51, 307
  6. Lerner AG, 1998, J Psychiatry, 155, 1460
  7. Lerner AG, 1997, J Psychiatry, 154, 437
  8. Lerner AG, 2001, J Psychiatry, 38, 133
  9. Lerner AG, 2002, J Psychiatry, 39, 100
  10. Lerner A, 2015, J Psychiatry, 52, 67
  11. Lerner A, 2014, J Psychiatry, 51, 277
  12. Casa B, 1589, J Neurol Sci, 2005, S504

Cited by

See all 27

Metadata

Authors
Doyle, M. A., Ling, S., Lui, L. M. W., Fragnelli, P., Teopiz, K. M., Ho, R., Di Vincenzo, J. D., Rosenblat, J. D., Gillissie, E. S., Nogo, D., Ceban, F., Jawad, M. Y., & McIntyre, R. S.
Affiliations
  • Western University (CA)
  • University Health Network (CA)
  • National University of Singapore (SG)
  • Mood Disorders Psychopharmacology Unit, Poul Hansen Depression Centre, University Health Network Toronto, ON, Canada
Corresponding author
Doyle, Marcus A.
Venue
Expert Opinion on Drug Safety
Published
2022-05-03
Volume
21
Issue
6
Pages
733-743
ISSN
  • 1474-0338 (ISSN-L)
  • 1744-764X
OpenAlex
W4224043710
Cited by
27
References
46
Citations by year
2026: 6 · 2025: 9 · 2024: 5 · 2023: 5 · 2022: 2
FWCI
0.88
Type
journal article
Language
en
Open access
closed
Locations
  • Expert Opinion on Drug Safety (publishedVersion)
  • PubMed (publishedVersion)
  • National University of Singapore (submittedVersion)
  • Rare & Special e-Zone (The Hong Kong University of Science and Technology) (submittedVersion)
Topics
  • Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Hallucinations in medical conditions
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Keywords
hallucinogen persisting perception disorder, hallucinogens, psychedelics, prevalence, risk factors, prevention, treatment, pathophysiology, hallucinations, mental illness, drug safety
MeSH terms
Hallucinations, Hallucinogens, Humans, Perceptual Disorders, Risk Factors, Prevalence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Hallucinogen persisting perceptual disorder: a scoping review covering frequency, risk factors, prevention, and treatment. https://app.cochat.ai/papers/10.1080/14740338.2022.2063273
The paper
Doyle, M. A., Ling, S., Lui, L. M. W., Fragnelli, P., Teopiz, K. M., Ho, R., Di Vincenzo, J. D., Rosenblat, J. D., Gillissie, E. S., Nogo, D., Ceban, F., Jawad, M. Y., & McIntyre, R. S. (2022). Hallucinogen persisting perceptual disorder: a scoping review covering frequency, risk factors, prevention, and treatment. Expert Opinion on Drug Safety. https://doi.org/10.1080/14740338.2022.2063273

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.